MS-818 free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534796

CAS#: 104966-11-2

Description: MS-818 free base is a bioactive chemical.

Chemical Structure

img
MS-818 free base
CAS# 104966-11-2
Instruction

Theoretical Analysis

MedKoo Cat#: 534796
Name: MS-818 free base
CAS#: 104966-11-2
Chemical Formula: C11H15N5O
Exact Mass: 233.13
Molecular Weight: 233.275
Elemental Analysis: C, 56.64; H, 6.48; N, 30.02; O, 6.86

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MS-818 free base; MS-818; MS 818; MS818

IUPAC/Chemical Name: 5H-Pyrrolo(3,4-d)pyrimidin-5-one, 6,7-dihydro-6-methyl-2-(1-piperazinyl)-

InChi Key: MLVNBIZLVSIUJS-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H15N5O/c1-15-7-9-8(10(15)17)6-13-11(14-9)16-4-2-12-3-5-16/h6,12H,2-5,7H2,1H3

SMILES Code: O=C1N(C)CC2=NC(N3CCNCC3)=NC=C21

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 233.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sugaya K, Vaidya M. Stem Cell Therapies for Neurodegenerative Diseases. Adv Exp Med Biol. 2018;1056:61-84. doi: 10.1007/978-3-319-74470-4_5. PMID: 29754175.


2: Kanemura M, Abe M, Ueda M, Ueki M, Awaya A, Sato Y. MS-818 accelerates mobilization of endothelial progenitor cells and differentiation to endothelial cells. Endothelium. 2004 Sep-Dec;11(5-6):221-30. doi: 10.1080/10623320490904089. PMID: 15763941.


3: Sanjo N, Owada K, Kobayashi T, Mizusawa H, Awaya A, Michikawa M. A novel neurotrophic pyrimidine compound MS-818 enhances neurotrophic effects of basic fibroblast growth factor. J Neurosci Res. 1998 Dec 1;54(5):604-12. doi: 10.1002/(SICI)1097-4547(19981201)54:5<604::AID-JNR5>3.0.CO;2-W. PMID: 9843151.


4: Sugiyama N, Yoshimura A, Fujitsuka C, Iwata H, Awaya A, Mori S, Yoshizato H, Fujitsuka N. Acceleration by MS-818 of early muscle regeneration and enhanced muscle recovery after surgical transection. Muscle Nerve. 2002 Feb;25(2):218-29. doi: 10.1002/mus.10028. PMID: 11870690.


5: Jiang XM, Ohnishi A, Yamamoto T, Murai Y, Awaya A, Ikeda M. The effect of MS-818, a pyrimidine compound, on the regeneration of peripheral nerve fibers of mice after a crush injury. Acta Neuropathol. 1995;90(2):130-4. doi: 10.1007/BF00294311. PMID: 7484087.


6: Fukuyama R, Ohta M, Ohta K, Saiwaki T, Fushiki S, Awaya A. A synthesized pyrimidine compound, MS-818, promotes walking function recovery from crush injury of the sciatic nerve through its indirect stimulation of Schwann cells. Restor Neurol Neurosci. 2000;17(1):9-16. PMID: 11490072.


7: Watanabe S, Wang XE, Hirose M, Osada T, Yoshizawa T, Tanaka H, Itatsu T, Nakajima M, Yamamoto J, Miwa H, Miyazaki A, Awaya A, Sato N. A neurotrophic pyrimidine compound, MS-818, enhances EGF-induced restoration of gastric epithelial wounds in vitro. J Clin Gastroenterol. 1998;27 Suppl 1:S105-9. doi: 10.1097/00004836-199800001-00017. PMID: 9872506.


8: Yasuhara S, Kashiwagi S, Ito H, Awaya A. The neurotrophic pyrimidine heterocyclic compound MS-818 promotes the angiogenesis induced by basic FGF. Int J Clin Pharmacol Res. 1995;15(5-6):167-74. PMID: 8835614.


9: Yoshikawa M, Saura R, Mizuno K, Awaya A. The effect of MS-818, newly synthesized pyrimidine compound, on fracture repair. Kobe J Med Sci. 2000 Dec;46(6):265-82. PMID: 11501015.


10: Itoh S, Samejima H, Shinomiya K, Awaya A. The effect of neurotrophic pyrimidine heterocyclic compounds, MS-818 and MS-430, on the regeneration of injured peripheral nerves. Restor Neurol Neurosci. 1999;14(4):265-273. PMID: 12671247.


11: Mitsuyama T, Kawamata T, Yamane F, Awaya A, Hori T. Role of a synthetic pyrimidine compound, MS-818, in reduction of infarct size and amelioration of sensorimotor dysfunction following permanent focal cerebral ischemia in rats. J Neurosurg. 2002 Jun;96(6):1072-6. doi: 10.3171/jns.2002.96.6.1072. PMID: 12066909.


12: Torigoe K, Awaya A. A newly synthesized neurotropic pyrimidine compound, MS-818, may activate migratory schwann cells in peripheral nerve regeneration. Brain Res. 1998 Mar 23;787(2):337-40. doi: 10.1016/s0006-8993(97)01491-1. PMID: 9518680.


13: Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin Pharmacother. 2008 Jun;9(9):1575-83. doi: 10.1517/14656566.9.9.1575. PMID: 18518786.


14: Shimoda N, Mutou Y, Shimura N, Tsukimoto M, Awaya A, Kojima S. Effect of heterocyclic pyrimidine compounds on UVB-induced cell damage in human keratinocytes and on melanogenesis in mouse B16 cells. Biol Pharm Bull. 2010;33(5):862-8. doi: 10.1248/bpb.33.862. PMID: 20460767.


15: Captur G, Gatehouse P, Keenan KE, Heslinga FG, Bruehl R, Prothmann M, Graves MJ, Eames RJ, Torlasco C, Benedetti G, Donovan J, Ittermann B, Boubertakh R, Bathgate A, Royet C, Pang W, Nezafat R, Salerno M, Kellman P, Moon JC. A medical device-grade T1 and ECV phantom for global T1 mapping quality assurance-the T1 Mapping and ECV Standardization in cardiovascular magnetic resonance (T1MES) program. J Cardiovasc Magn Reson. 2016 Sep 22;18(1):58. doi: 10.1186/s12968-016-0280-z. PMID: 27660042; PMCID: PMC5034411.


16: Ohbayashi K, Inoue HK, Awaya A, Kobayashi S, Kohga H, Nakamura M, Ohye C. Peripheral nerve regeneration in a silicone tube: effect of collagen sponge prosthesis, laminin, and pyrimidine compound administration. Neurol Med Chir (Tokyo). 1996 Jul;36(7):428-33. doi: 10.2176/nmc.36.428. PMID: 8741371.


17: Koyama Y, Awaya A, Ishikawa N, Fujita S, Tomino I, Yokoyama K, Araki S, Takesue M, Kato K, Ishiguro M, Kitahara T, Kihara N, Baba A. Neurotropic pyrimidine heterocyclic compounds. II. Effects of novel neurotropic pyrimidine derivatives on astrocytic morphological differentiation. Biol Pharm Bull. 1997 Feb;20(2):138-41. doi: 10.1248/bpb.20.138. Erratum in: Biol Pharm Bull 1997 Jul;20(7):823. PMID: 9057974.


18: Baker-Jarvis J. Time-dependent entropy evolution in microscopic and macroscopic electromagnetic relaxation. Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Dec;72(6 Pt 2):066613. doi: 10.1103/PhysRevE.72.066613. Epub 2005 Dec 22. PMID: 16486084.


19: Baker-Jarvis J, Kabos P, Holloway CL. Nonequilibrium electromagnetics: Local and macroscopic fields and constitutive relationships. Phys Rev E Stat Nonlin Soft Matter Phys. 2004 Sep;70(3 Pt 2):036615. doi: 10.1103/PhysRevE.70.036615. Epub 2004 Sep 29. PMID: 15524664.


20: Baker-Jarvis J, Riddle B, Janezic MD. Dielectric polarization evolution equations and relaxation times. Phys Rev E Stat Nonlin Soft Matter Phys. 2007 May;75(5 Pt 2):056612. doi: 10.1103/PhysRevE.75.056612. Epub 2007 May 25. PMID: 17677191.